Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atypical Teratoid Rhabdoid Tumors (ATRT) Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 6:48 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated
Interventions
GPC2-CAR T cells, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced May 21, 2026, 6:48 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
Interventions
Panobinostat
Drug
Lead sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Other
Eligibility
Up to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 21, 2026, 6:48 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 6:48 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Brain Tumor Recurrent
Interventions
Methotrexate, Etoposide, Ommaya Reservoir
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced May 21, 2026, 6:48 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced May 21, 2026, 6:48 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced May 21, 2026, 6:48 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Atypical Teratoid Rhabdoid Tumor, Central Nervous System Rhabdoid Tumor
Interventions
21.15.GPC3-CAR T Cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 6:48 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Interventions
Modified Measles Virus, Modified Measles Virus Lumbar Puncture
Biological
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
12 Months to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced May 21, 2026, 6:48 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Interventions
Lumber Puncture, Blood Specimen Collection, Magnetic resonance imaging (MRI), Gemcitabine, Paxalisib, Tumor Biopsy
Procedure · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 6:48 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced May 21, 2026, 6:48 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced May 21, 2026, 6:48 PM EDT